我们的网站为什么显示成这样?

可能因为您的浏览器不支持样式,您可以更新您的浏览器到最新版本,以获取对此功能的支持,访问下面的网站,获取关于浏览器的信息:

|本期目录/Table of Contents|

基于“伏气学说”的清透法治疗变应性鼻炎的随机对照临床研究(PDF)

《云南中医学院学报》[ISSN:1000-2723/CN:53-1048/R]

期数:
2017年05期
页码:
44-48
栏目:
临床研究
出版日期:
2017-12-16

文章信息/Info

Title:
Randomized Controlled Clinical Study on Heatclearing and Pathogenicexpelling Method Based on Latent Pathogen Theory in the Treatment of Allergic Rhinitis
作者:
孙路路尤德明张颖王海瑞褚瑞萌王玉宝徐松波吴目武
蚌埠市第一人民医院,安徽 蚌埠 233000
Author(s):
SUN Lulu YOU Deming ZHANG Yin WANG Hairui CHU Ruimeng WANG Yubao XU Songbo WU Muwu
The First People’s Hospital of Bengbu City, Bengbu 233000, China
关键词:
变应性鼻炎伏气学说清透法随机对照试验复发率
Keywords:
allergic rhinitis latent pathogen theory heatclearing and pathogenicexpelling method randomized controlled trial recurrence rate
分类号:
R276.1
DOI:
10.19288/j.cnki.issn.1000-2723.2017.05.010
文献标识码:
A
摘要:
目的 评价基于“伏气学说”的清透法治疗变应性鼻炎患者的临床疗效和安全性。方法 120例患者随机分为3组,中药组、西药组及中西药组各40例,中药组给予清透法中药(200mL/次,2次/d),西药组给予枸地氯雷他定片(8.8mg/次,1次/d),中西药组给予清透法中药和枸地氯雷他定片,各组1个疗程连续1周治疗,共治疗3个疗程,每次间隔2d。比较3组患者治疗前、疗程结束后、随访1年患者症状评分、生活质量评分,并观察各组复发率及安全性。结果 治疗结束后,3组症状评分及生活质量评分均较治疗前明显降低(P<0.01)。随访结束,西药组症状评分和生活质量评分较治疗前无统计学差异(P>0.05),明显高于中药组、中西药组(P<0.01);中药组、中西药组较治疗前均明显降低(P<0.01),组间相比较无统计学差异(P>0.05)。3月内各组患者复发率无统计学差异(P>0.05),3月后中药组、中西药组明显低于西药组(P<0.01),中药组与中西药组相比较无统计学差异(P>0.05)。3组患者均未发生明显试验相关不良反应。结论 基于“伏气学说”的清透法中药和枸地氯雷他定片均能有效改善患者症状评分和生活质量评分,远期疗效及改善复发率方面,清透法中药优于枸地氯雷他定片,且临床安全性良好。
Abstract:
Objective Evaluation on clinical efficacy and safety of heatclearing and pathogenicexpelling method based on theory of latent pathogen in the treatment of patients with allergic rhinitis. Methods A total of 120 patients with allergic rhinitis were randomly divided into three groups: traditional Chinese medicine(TCM) group treated with heatclearing and pathogenicexpelling method(200mL/times, 2 times/D), western medicine group with Desloratadine Citrate Disodium Tablets(8.8mg/times, 1 times/D), and integrated Chinese and western medicine group with heatclearing and pathogenicexpelling method combined with Desloratadine Citrate Disodium Tablets, Each treatment group was treated with continuous 1W for 1 courses, a total of 3 courses of treatment, each interval of 2D.40 cases in each group. Allergic rhinitis symptom score(ARSS) and quality of life score(QOLS) before, immediately after treatment, and after 1-year follow-up were compared among the three groups; and the recurrence rates and clinical safety were observed in all groups. Results After treatment, ARSS and QOLS decreased notably in all groups compared with those before treatment(P<0.01). After the end of follow-up, the ARSS and QOLS in western medicine group showed insignificant differences compared with those before treatment(P>0.05), but were evidently higher than those in TCM group and integrated Chinese and western medicine group(P<0.01). The scores also decreased prominently in TCM group and integrated Chinese and western medicine group(P<0.01), but the difference was not significant between these two groups(P>0.05). There was insignificant difference among the three groups in the recurrence rate within 3 months(P>0.05). The recurrence rate was notably lower in both TCM group and integrated Chinese and western medicine group than in western medicine group(P<0.01) 3 months later; however there was insignificant difference between TCM group and integrated Chinese and western medicine group(P>0.05). No obvious trial related adverse reactions were observed in the three groups. Conclusion Both TCM of heatclearing and pathogenicexpelling method based on latent pathogen theory and Desloratadine Citrate Disodium Tablets can effectively improve the ARSS and QOLS. In terms of long-term clinical efficacy and recurrence rate improvement, TCM of heatclearing and pathogenicexpelling method is superior to Desloratadine Citrate Disodium Tablets, with greater clinical safety.

参考文献/References

[1] 中华医学会耳鼻咽喉头颈外科学分会鼻科学组. 变应性鼻炎诊断和治疗指南(2015年,天津)[J]. 中华耳鼻咽喉头颈外科杂志,2016,51(1):6-24.
[2] Juniper EF. Measuring health-related quality of life in rhinitis[J]. J Allergy Clin Immunol,1997,99(2):742-749.
[3] 中华耳鼻咽喉头颈外科杂志编辑委员会. 变应性鼻炎的诊治原则和推荐方案(2004年,兰州)[J]. 中国社区医师,2005,40(3):166-167.
[4] 邰旭辉,龙晓宏,朱宝玉,等. 辽宁地区变应性鼻炎流行病学调查及相关危险因素分析[J]. 临床军医杂志,2017,45(3):275-277.
[5] 魏肖云,李萌,汪受传. 中医药治疗变应性鼻炎机理研究进展[J]. 辽宁中医药大学学报,2014(6):168-170.
[6] 李芸,周家璇,陈晓宇,等. 鼻敏爽胶囊对变应性鼻炎豚鼠模型Th1/Th2细胞因子表达的影响[J]. 云南中医学院学报,2014,37(5):24-26.
[7] 南京中医学院中医系. 黄帝内经灵枢译释[M]. 上海:上海科学技术出版社,1986:37-38.
[8] 清·王燕昌. 王新华点注.王氏医存[M]. 南京:江苏科学技术出版社,1985:108-109.
[9] 孙路路,褚瑞萌. 从“伏邪致病”论治变应性鼻炎浅析[J]. 河北中医,2017,39(6):912-915.
[10] 孙路路,尤德明,褚瑞萌,等. 桂枝汤加味治疗过敏性鼻炎临床疗效观察[J]. 新中医,2014(12):150-151.
[11] 金贤兰. 徐长卿药理作用及临床应用研究进展[J]. 现代医药卫生,2010,26(19):2947-2948.
[12] 朱海燕,吴贤波,金贤国,等. 酸味中药乌梅对肥大细胞脱颗粒及相关信号传导通路的影响[J]. 时珍国医国药,2015(9):2096-2098.
[13] 施嫣嫣,张丽,丁安伟. 墨旱莲化学成分及药理作用研究[J]. 吉林中医药,2011,31(1):68-70.
[14] 李福生,王茂泓. 从“伏邪”论治肾病综合征[J]. 中华中医药杂志,2017,32(3):1092-1094.
[15] 刘畅,孙路路,付征,等. 基于伏邪理论的清透法对ICU耐药菌肺部感染患者耐药菌清除率及脱机成功率的影响[J]. 北京中医药,2015(2):108-112.
[16] 李绍林,何伟,胡勇. 基于伏邪入络探讨原发性痛经的发生机制及治疗[J]. 世界中西医结合杂志,2017,12(6):741-743.
[17] 孔祥聿,黄琳,李海昌. 伏邪学说与系统性红斑狼疮发病的关系探析[J]. 中国中医急症,2016,25(3):384-386.

备注/Memo

备注/Memo:
* 基金项目: 2015年安徽省蚌埠市科学技术和知识产权局科技发展指导性项目(20150323)
收稿日期: 2017 - 09- 06
作者简介: 孙路路(1987-),男,医学硕士,主治医师,研究方向:中西医结合治疗心肺系疾病。E-mail:for2012@126.com
更新日期/Last Update: 2017-10-20